{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 63 of 92', 'CR845-CLIN3102', '8.6.5', 'Prior and Concomitant Medications', 'All medications will be coded using the World Health Organization Drug Dictionary. All', 'prior and concomitant medications will be listed and summarized separately by', 'Anatomical Therapeutic Chemical class 3 (ATC 3), Preferred Term, and treatment group.', 'The use of concomitant medications during the Double-blind and Discontinuation Period', 'will be summarized separately. Additionally, a coding listing of unique medications and', 'their corresponding coding will be presented.', '8.6.6', 'Antipruritic Medication', 'Prior and concomitant antipruritic medications will be summarized separately by study', 'period (Run-in, Double-blind, Discontinuation); summaries will be presented by', 'ingredient rather than by ATC codes.', '8.7', 'Efficacy Analysis', '8.7.1', 'Primary Efficacy Endpoint', 'The primary efficacy endpoint is defined as the proportion of patients achieving 3-point', 'improvement from baseline with respect to the weekly mean of the daily 24-hour Worst', 'Itching Intensity NRS at Week 12 (Days 79 to 85) of the Double-blind Treatment Period.', 'The weekly mean of the 24-hour Worst Itching Intensity NRS score will be defined as the', 'sum of the daily Worst Itching Intensity NRS scores reported during a specific week', 'during the Double-blind Treatment Period (eg, Days 2 to 8, Days 9 to 15, Days 16 to 22,', 'Days 79 to 85) divided by the number of days with nonmissing scores for that week. If', 'the daily worst itching score is missing for >3 days during a specific week, the', 'corresponding weekly mean worst itching score will be set to missing. The baseline', 'score will be defined as the average of the daily 24-hour Worst Itching Intensity NRS', 'scores collected over the Run-in Period, including pre-randomization assessments', 'collected on Day 1.', 'In the primary efficacy analysis, missing NRS data will be imputed using a multiple', 'imputation (MI) approach, assuming that patients who discontinue Double-blind', 'treatment early would have similar Worst Itching Intensity NRS scores as other patients', 'in their respective treatment arm that have complete data:', 'Intermittent missing NRS scores will first be imputed using the Markov Chain', 'Monte Carlo (MCMC) method implemented with the SAS MI procedure, which is', 'appropriate for non-monotonic missing data.', 'NRS scores missing after patients discontinue study drug early will then be', 'multiply imputed with the SAS MI procedure using a method appropriate for', 'monotone missingness (eg, regression statement). Details on the MI procedure', 'can be found in Appendix 14.8.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 65 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 64 of 92', 'CR845-CLIN3102', 'The proportion of patients who have an improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS score', '>3 points will be calculated for each imputed dataset. Differences between', 'CR845 0.5 mcg/kg and placebo with respect to the primary endpoint will be', 'compared using a logistic regression model containing terms for treatment group,', 'baseline NRS score, use of prior anti-itch medication, and presence of specific', 'medical conditions.', 'Results of the logistic regression on the multiply imputed data sets will be', 'summarized by the SAS MIANALYZE procedure.', 'The final p-value will be calculated using the Cui, Hung, Wang (CHW) procedure where', 'the z-score is a weighted average of the z-score at the interim and the z-score observed', 'for data collected after the interim, following the formula below.', 'Zfinal=Zinterim * V(n/N) + Zpost-interim * N(1 - n/N)', 'where n is the number of patients at the interim and N is the initial number of patients', 'planned (300).', 'Sensitivity analyses of the primary efficacy endpoint will be conducted to evaluate the', 'robustness of study results under different assumptions and imputation algorithms. For', 'each of these sensitivity analyses, the final p-value will be calculated based on the CWH', 'procedure, using the formula specified above.', 'Sensitivity 1: Early discontinuations as nonresponders', 'Patients who discontinue study drug early will be considered nonresponders. The', 'imputed data will be analyzed using a logistic regression model similar to the', 'primary analysis.', 'Sensitivity 2: Multiple imputation; missing not at random (MNAR)', 'This sensitivity analysis is an implementation of a pattern mixture model that', 'draws from different populations based on the reason for withdrawal.', 'Intermittent missing NRS scores will first be imputed using the MCMC', 'method with the SAS MI procedure, which is appropriate for non-monotonic', 'missing data.', 'For patients who discontinued study drug due to adverse events, NRS scores', 'missing after discontinuation will be imputed using the distribution of the', \"baseline value of all patients' daily worst itching score assuming a trimmed\", 'normal (from 4 to 10).', 'For patients who discontinue due to reasons other than adverse event, missing', 'NRS scores after patients discontinue study drug early will be multiply', 'imputed using multiple calls of the SAS MI procedure using data from', 'patients within the same treatment group that have complete data at that time.', 'The proportion of patients who have an improvement from baseline with', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 66 of 95']\n\n###\n\n", "completion": "END"}